Good MorningStocks ended the day lower after the S&P 500 initially reached an intra-day high. Even the tech-heavy NASDAQ finished in the red despite an additional 2% increase in NVIDIA stock. The VIX ended the day higher, as did gold.
One day doesn’t make a pattern, but with earnings season two weeks away, investors could be looking at economic indicators. If that’s the case, they got disappointing news from August home sales, which were down 4.7%.
Their attention will now shift to the final reading on second-quarter GDP, which will be released on Thursday morning. On Friday, investors will get the latest reading of the PCE index.
Investors aren’t expecting any surprises at this time. But as the saying goes, “That’s why they play the games.” Any negative surprises could fuel recession fears and push stocks lower. Featured: Wall Street’s quietly buying these 3 AI infrastructure plays (Ad) 
|
Retail/Wholesale | |
When companies announce their quarterly earnings results, they can often get sucked into the market's price action for that day, especially if other news or economic data come in to trump the importance of the quarterly release for that stock. That is the case today with shares of AutoZone Inc. ... Read the Full Story |
|
From Our Partners | | BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid.
The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned. | | Get the name, the ticker, and exactly how to buy it |
|
Markets | |
A treasury bill is a short-term government debt security offering a high level of security and low risk. When you purchase a treasury bill, you essentially lend money to the government to complete short-term projects with timelines of less than one year. Because these investments are backed by the... Read the Full Story |
|
Medical | |
Edgewise Therapeutics (NASDAQ: EWTX) is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks. Yet, with still only a market cap of $2.4 billion, is there still time to get in? I’ll examine recent n... Read the Full Story |
|
From Our Partners | | See the Signals Most Traders Miss
We monitor subtle shifts in order flow, volume patterns, and early trend behavior.
Stock News Trends highlights moves long before they hit mainstream screens. | | Join Free — Start Tracking Early Market Data |
|
Markets | |
On September 27, 2024, investors will get the latest reading on inflation from the Personal Consumption Expenditures (PCE) index. In August, the reading came in at 2.5%. This means that year-over-year prices were increasing by 2.5%.
It’s no wonder that many consumers, particularly low- an... Read the Full Story |
|
Technology | |
Palantir Technologies Inc. (NYSE: PLTR) began trading as a member of the S&P 500 index on September 23, 2024. Inclusion in the index was a long-time goal of Palantir. It’s also a significant milestone for retail investors who have largely driven the growth of PLTR stock since it went pub... Read the Full Story |
|
From Our Partners | | With OpenAI and Anthropic moving closer to the IPO spotlight, AI excitement could spill into several public-market sectors this summer - and most investors may chase the obvious names too late.
A free report identifies 7 stocks positioned around themes that could matter most this summer: AI infrastructure, energy demand, travel, entertainment, home improvement, and more. Built for a market where leadership may rotate quickly. | | Download 7 Best Stocks to Own in Summer 2026 for free |
|
Medical | |
With the stock markets trading near highs again and the start of a lower interest rates cycle, the backdrop for mergers, spin-offs, and acquisitions continues to improve. Elevated stock prices are just as good as currency when trying to acquire another company. The Sept. 24, 2024, announcement tha... Read the Full Story |
|
Basic Materials | |
Gold’s record-breaking surge continues, with the precious commodity now up close to 40% over one year, outpacing the stock market’s benchmark, which gained 32% over the same time. As gold ETFs and several gold mining stocks soar, the question arises: Is now the time to buy, or should i... Read the Full Story |
|
Auto/Tires/Trucks | |
After a promising start to the summer, shares of electric vehicle (EV) maker Rivian Automotive, Inc. (NASDAQ: RIVN) have been struggling for upward momentum. A solid 125% rally from April through July looked promising, especially as the stock was coming off an all-time low. However, a weaker-tha... Read the Full Story |
|
Industrials | |
Caterpillar Inc. (NYSE: CAT) is the leading manufacturer of heavy machinery, equipment, and vehicles for construction and mining. It operates in the industrial products sector, competing with heavy machinery makers Deer & Co. (NYSE: DE), CNH Industrial N.V. (NYSE: CNH), and Terex Co. (NYSE: ... Read the Full Story |
|
Markets | |
Like those represented by the iShares Russell 2000 ETF (NYSE: IWM), small-cap stocks are especially sensitive to interest rate changes. Historically, after the Federal Reserve implements rate cuts, all market cap sectors tend to rally, but small caps often outperform their larger-cap peers.
Thi... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland. | | View Today's Stock Pick |
|
